The EA-37B is meant to disrupt enemy communications, playing havoc on their command and control and shattering their kill chains.
Completed enrollment of Cohort C in the Phase 1 ALLOHAâ„¢ trial; patients to be treated with commercial-ready manufacturing processReceived FDA ...
Q4 2025 Earnings Call February 25, 2026 10:00 AM ESTCompany ParticipantsMichael Hall - Vice President of Investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results